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Abstract:  Protein toxins confer a defense against predation/grazing or a superior 
pathogenic competence upon the producing organism. Such toxins have been perfected 
through evolution in poisonous animals/plants and pathogenic bacteria. Over the past five 
decades, a lot of effort has been invested in studying their mechanism of action, the way 
they contribute to pathogenicity and in the development of antidotes that neutralize their 
action. In parallel, many research groups turned to explore the pharmaceutical potential of 
such toxins when they are used to efficiently impair essential cellular processes and/or 
damage the integrity of their target cells. The following review summarizes major 
advances in the field of toxin based therapeutics and offers a comprehensive description of 
the mode of action of each applied toxin. 
Keywords: toxins; targeting; pseudomonas exotoxin A; diphtheria toxin; ricin; anthrax; 
immunotoxins; suicide gene 
 
1. Introduction 
The secretion of polypeptides by prokaryotic and eukaryotic cells is an elaborate mechanism 
enabling the execution of essential processes like active modulation of the environment, enzymatic 
processing of nutrients and communication with other cells. However, a unique group of secreted 
polypeptides, the secreted toxins, plays a different role in maintaining the fitness of the organism, and 
have been perfected through evolution with the aim of damaging other living organisms. As such, 
toxins provide their producer with advantages such as enhanced defense capabilities or pathogenic 
OPEN ACCESSToxins 2010, 2  
 
 
2520
competence. Most natural protein toxins can be divided into three major groups: 1. Toxins that damage 
the cell by disrupting membrane integrity; 2. Toxins that disrupt the normal electrical activity of the 
nervous system of the intoxicated organism; 3. Toxins that disrupt or interfere with cellular processes 
by virtue of an enzymatic activity. Members of groups 1 and 2 may affect the target cells by enzymatic 
or non-enzymatic activities. Some members of the third group, on which this review is focused, are 
extremely toxic polypeptides that have the capability of self translocation into the cell cytoplasm 
where they execute their activity that, in most cases, leads to death of the intoxicated cell. Scientific 
advances in the last decades facilitated the processing and manipulation of biological substances; 
among which are toxic polypeptides and their encoding genes. By using different strategies for 
directing toxic moieties to diseased cells/tissues (Figure 1), scientists have established a new niche in 
clinical research, called “toxin-based therapy”.  
Figure 1. Three targeting strategies in toxin based therapy. Ligand targeted toxins: a ligand 
(antibody, antibody derivative, cytokine, etc.), which specifically binds to a disease related 
cell-surface antigen/receptor is linked to a toxic moiety, preferentially as a replacement to 
the natural cell binding domain of that toxin. Upon administration to patients, the construct 
selectively binds, is internalized and intoxicates diseased cells, sparing healthy cells that do 
not display the target on their surface. Protease activated toxins: the toxin is engineered to 
be cleaved and activated by a disease-related intracellular or extracellular protease. Toxin 
cleavage may enhance cell-binding and/or translocation, stabilization or catalytic activity 
of the toxic moiety specifically in protease expressing cells, leading to their eradication. 
Toxin based suicide gene therapy: a DNA construct, encoding for a toxic polypeptide 
whose expression is regulated by a specific transcription regulation element (TRE), is 
delivered to a heterogeneous cell population. However, intoxication occurs only in 
diseased cells that express an active disease-associated transcription factor (DATF) that 
specifically binds to the TRE and activates the transcription machinery (RP: RNA 
polymerase). 
 Toxins 2010, 2  
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The following review provides highlights of several prominent studies in this field; products from 
some of these studies have been evaluated clinically, or are currently undergoing clinical evaluation, 
mostly in context of oncological diseases. Constructs were classified by the targeting strategy used, 
namely surface antigen/receptor specific targeting (immunotoxins), transcriptional targeting (suicide 
genes) and protease specific targeting (Protease activated toxins). Emphasis has been put on constructs 
in which the toxic moiety is a derivative of the bacterial toxins produced by Corynebacterium 
diphtheria (Diphtheria toxin), Pseudomonas aeruginosa (Pseudomonas exotoxin A) and Bacillus 
anthrachis (Anthrax toxin); or plant produced toxins (ribosome inactivating proteins). For recent 
reviews about the botulinum toxin, a bacterial neurotoxin which is commonly applied in today’s 
medicine and is not covered in the following pages, see [1–4]. 
2. Ligand Targeted Toxins—Immunotoxins 
The term “immunotoxin” classically refers to molecules which consist of a protein toxin linked to a 
targeting moiety derived from the immune system (such as an antibody or an antibody fragment); but 
frequently expanded to include other target-specifying ligands (such as a cytokine). The idea of 
development of a “magic bullet” that has a specific attraction to a disease-causing target, avoiding 
healthy body cells, was originally suggested by Paul Ehrlich over 100 years ago [5–7]. However, it 
was only in the 1970s that therapeutic agents composed of toxins conjugated to antibodies against cell 
surface antigens were shown to kill tumor cells [8,9]. Since then, many hybrid molecules consisting of 
a toxin coupled with a specific targeting antibody/ligand were developed; most of them are targeted 
against tumor cells [10] (Figure 1).  
First generation immunotoxins were prepared by chemically conjugating antibodies to natural-intact 
toxin units or to toxins with attenuated cell binding capability. However, these constructs were 
heterogeneous and unspecific because of the multiplicity of potential sites available for chemical 
conjugation and as the presence of the cell binding domain of the toxin led to intoxication of “normal” 
cells, respectively. Immunotoxins of the second generation were also based on chemical conjugation 
between the targeting moiety and the toxin. Nevertheless, cumulative knowledge on the structure and 
function of the toxins enabled the removal of their native non-specific cell binding domain, generating 
much more target-specific immunotoxins when conjugated to monoclonal antibodies. Although more 
specific, and thus better tolerated by animals, immunotoxins from the second generation were still 
chemically heterogeneous and their large size hindered them from penetrating solid tumors. In order to 
avoid heterogeneity, improve tumor penetration and reduce production complexity and costs, 
recombinant DNA techniques were applied in the production of third generation immunotoxins. In 
these constructs, which are mostly produced in the bacterium Escherichia coli, the cell binding domain 
of the toxin is genetically replaced with a ligand or with the Fv portion of an antibody in which its 
light and heavy chain variable fragments are either genetically linked (scFv) or held together by a 
disulfide bond (dsFv) (Figure 2).  
Among the bacterial toxins that were used for the construction of immunotoxins, the most common 
are diphtheria toxin and pseudomonas exotoxin A, which are naturally produced by the Gram-positive, 
aerobic  Corynebacterium diphtheria and by the Gram-negative, aerobic Pseudomonas aeruginosa, 
respectively. Plant derived toxins, which belong to a group of toxins denoted “ribosome inactivating Toxins 2010, 2  
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proteins” (RIPs), were also used in the preparation of immunotoxins. Among them, ricin, saporin and 
pokeweed antiviral protein (PAP), produced by Ricinus communis,  Saponaria officinalis and 
Phytolacca americana, respectively, were most commonly used. All of these toxins are extremely 
potent and exert their toxicity by enzymatically inhibiting the protein synthesis machinery of 
eukaryotic cells (for additional reviews on immunotoxins, see [10–16]). 
Figure 2. Three generations of immunotoxins. First generation immunotoxins were 
prepared by chemically conjugating antibodies/ligands to intact toxin units or to toxins 
with attenuated cell binding capability. Reducible or non-reducible chemical 
bonds/linkers were used for that purpose; the first was generally applied when the 
conjugation site was positioned on part of the toxin that translocates to the cytosol. In 
second generation immunotoxins, truncated toxins that lack a cell binding domain were 
chemically conjugated to a targeting moiety. In third generation immunotoxins, mostly 
produced in the bacterium Escherichia coli, the cell binding domain of the toxin is 
genetically replaced with a ligand or with the Fv portion of an antibody in which the light 
and heavy chain variable fragments are either genetically linked (scFv) or held together 
by a disulfide bond (dsFv). 
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In the next chapter, selected immunotoxins will be classified by their toxic moiety (diphtheria toxin, 
pseudomonas exotoxin A or RIPs derivatives), and a short review on the mechanism of action of their 
coupled toxins will be followed by a brief description of their disease-causing target, targeting 
antibody/ligand, and current status of clinical trials. Information about these and other clinically 
evaluated immunotoxins is summarized in Table 1. For ligand targeted toxins, we provide detailed 
examples of toxin based therapies that were evaluated in patients and do not detail the hundreds of 
examples of molecules that were evaluated pre-clinically. Toxins 2010, 2  
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Table 1. Clinically evaluated/under evaluation immunotoxins. 
Construct  
Name 
Targeting 
Moiety 
Toxic  
Moiety 
Toxin 
Source 
Target Indication 
Clinical 
Trial 
Phase 
References
DAB389IL2 
(Denileukin 
Diftitox) 
IL-2 DAB389 DT  IL-2R 
CTCL,NHL, CLL, 
NSCLC, GVHD, psoriasis, 
melanoma, ovarian, breast, 
kidney cancers 
I,II,III,IV
*FDA 
approved
For 
CTCL 
treatment
 [17–25] 
DAB486IL2  IL-2 DAB486 DT  IL-2R 
NHL,HD,CLL, 
CTCL,KS,RA 
I/II   [26–31] 
Tf-CRM107 
(TransMID) 
Transferrin  CRM107  DT  TfR  Brain and CNS tumors  I, III   [32–34] 
DT388-GM-CSF  GM-CSF DT388 DT  GM-CSFR AML  I    [35] 
DAB389EGF  EGF DAB389 DT  EGFR 
EGFR-expressing 
carcinoma 
I/II   [11] 
A-dmDT390-
bisFV (UCHT1) 
bisFv DT390 DT  CD3ε  T-cell lymphoma/leukemia  I/II   [36,37] 
DT388-IL3 
Variant 
IL-3 
DT388  DT  IL-3R  AML, MDS  I/II   [38] 
OVB3-PE  MAb  Full length PE  PE 
Ovarian 
antigen 
Ovarian cancer  I   [39] 
ERB-38  dsFv PE38  PE 
erbB2/ 
HER2 
Breast, esophageal cancers  I   [40] 
SS1(dsFv)PE38 
(SS1P) 
dsFv PE38  PE  Mesothelin
Mesothelioma, ovarian, 
pancreatic cancers 
I   [41,42] 
B3(Fv)-PE38 
(LMB-7) 
scFv  PE38  PE  Lewis Y  Adenocarcinoma  I   [10] 
LMB-1  MAb  PE38  PE  Lewis Y  Adenocarcinoma  I   [43] 
RFB4(dsFv)-
PE38 
(BL22/CAT3888) 
dsFv  PE38  PE  CD22  NHL,CLL,HCL, ALL  I,II   [44–47] 
LMB-2  scFv  PE38  PE  CD25  Leukemia, lymphoma  II   [48] 
scFv(FRP5)-ETA  scFv PE40  PE 
erbB2 
/HER2 
Melanoma, Breast, colon 
cancers 
I   [49,50] 
TP40  TGFα  Modified PE40  PE  EGFR  Bladder cancer  I   [51] 
TP38  TGFα PE38  PE  EGFR  Glioblastoma  II    [52–54] 
BR96sFv-PE40 
(SGN-10) 
scFv  PE40  PE  Lewis Y  Adenocarcinoma  I   [55] 
B3(dsFv)-PE38 
(LMB-9) 
dsFv  PE38  PE  Lewis Y  Adenocarcinoma  I   [10] 
IL4(38-37) 
PE38KDEL 
(NBI-3001) 
Circularly 
permuted 
IL-4 
Modified PE38  PE  IL-4R 
Brain, CNS, kidney, lung, 
breast cancers 
I,II   [56–58] Toxins 2010, 2  
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Table 1. Cont. 
Construct  
Name 
Targeting 
Moiety 
Toxic  
Moiety 
Toxin 
Source 
Target Indication 
Clinical 
Trial 
Phase 
References
Mutated 
RFB4(dsFv)-
PE38 
(HA22/CAT-
8015) 
dsFv PE38  PE  CD22 
HCL, ALL, NHL CLL, 
PLL, SLL 
I   [59,60] 
IL13-PE38QQR 
(cinterdekin 
besudotox) 
IL-13  Modified PE38  PE  IL-13R  Glioma  I/II, III   [61–64] 
RFB4-Fab'-dgA  Fab' 
Deglycosylated 
RTA 
Ricin CD22  B-NHL  I    [65] 
RFB4-dgA 
(IMTOX-22) 
MAb 
Deglycosylated 
RTA 
Ricin  CD22  B-NHL, CLL  I   [66,67] 
HD37-dgA 
(IMTOX-19) 
MAb 
Deglycosylated 
RTA 
Ricin CD19  NHL  I    [68,69] 
RFB4-dgA + 
HD37-dgA 
(Combotox) 
MAb 
Deglycosylated 
RTA 
Ricin 
CD22, 
CD19 
NHL, ALL  I   [70,71] 
RFT5-dgA 
(IMTOX-25) 
MAb 
Deglycosylated 
RTA 
Ricin CD25 
HD, CTCL, melanoma, 
GVHD 
I,II   [72–76] 
Ki-4.dgA  MAb 
Deglycosylated 
RTA 
Ricin CD30  HD,NHL  I    [75,77] 
Anti-B4-bR  MAb  Blocked ricin  Ricin  CD19  B-NHL  II   [78–81] 
Anti-CEA-bR  MAb Blocked  ricin Ricin  CEA  Colorectal cancer  I/II   [82] 
N901-bR  MAb  Blocked ricin  Ricin  CD56  SCLC  I   [83–85] 
Anti-CD7-dgA 
(DA7) 
MAb 
Deglycosylated 
RTA 
Ricin CD7  T-NHL  I    [86] 
Anti-CD3-dgA 
+Anti-CD7-dgA 
MAb 
Deglycosylated 
RTA 
Ricin  CD3, CD7 GVHD  I/II   [87] 
CD5-IC, CD5 
Plus 
MAb  RTA  Ricin  CD5  RA, SLE, diabetes mellitus  I,II   [88–92] 
H65-RTA  MAb  RTA  Ricin  CD5  CTCL, GVHD  I, I/II   [93–95] 
T101-RTA  MAb RTA Ricin  CD5  CLL  I    [96–98] 
MDX-RA  MAb RTA Ricin 
Human 
lens 
epithelial 
antigen 
Posterior capsule 
opacification (secondary 
cataract) 
III   [99–101] 
XomaZyme-Mel 
(XMMME-001-
RTA) 
MAb RTA Ricin 
Melanoma 
antigen 
Melanoma 
 
I/II   [102–107]
XomaZyme-791 
(79IT/36-RTA) 
MAb RTA Ricin 
72kDa 
TAA 
Colorectal cancer  I   [108–110]
454A12-rRA  MAb  RTA  Ricin  TfR  Leptomeningeal neoplasia  I   [111] Toxins 2010, 2  
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Table 1. Cont. 
Construct  
Name 
Targeting 
Moiety 
Toxic  
Moiety 
Toxin 
Source 
Target Indication 
Clinical 
Trial 
Phase 
References
260F9-rRTA  MAb RTA Ricin 
55 kDa 
breast 
cancer 
antigen 
Breast cancer  I   [112,113]
B43-PAP  MAb PAP PAP  CD19  ALL  I    [114] 
TXU-PAP  MAb  PAP  PAP  CD7  HIV-1 infection  I   [115] 
BER-H2-Sap6  MAb Saporin  Saporin  CD30  HD  I   [116] 
HUM-195/rGel  MAb Gelonin  Gelonin  CD33  AML,CML  I   [117] 
BDI-1-MD  MAb Momordin  Momordin
Bladder 
carcinoma 
antigen 
Bladder cancer  I   [118] 
Abbreviations: MAb: monoclonal antibody; dsFv: disulfide-stabilized Fv antibody fragment; scFv: A single-
chain (genetically linked) variable fragment; bisFv: two Fv fragments connected via a disulfide bond;   
Fab': fragment antigen-binding (one constant / one variable domain of each heavy and light chain connected 
by a disulfide bond); IL(R): interleukin (receptor); DT: diphtheria toxin; DAB389, DAB486, DT388, DT390: 
truncated forms of DT that lack receptor-binding activity; CRM107: a mutated full-length diphtheria toxin 
that lack receptor-binding activity; PE: pseudomonas exotoxin A; PE38, PE40: truncated forms of PE that 
lack the receptor-binding domain Ia; RTA: ricin toxin A; HIV: human immunodeficiency virus;   
CTCL: cutaneous T cell lymphoma; NHL: non-Hodgkin’s lymphoma; MDS: myelodysplastic syndrome; 
ALL: acute lymphoblastic leukemia; SLL: small lymphocytic lymphoma; GVHD: graft versus host disease; 
CNS: central nervous system; EGF(R): epidermal growth factor (receptor); TGF(R): transforming growth 
factor (receptor) AML: acute myelogenous leukemia; CML: chronic myelogenous leukemia; CLL: chronic 
lymphocytic leukemia; HD: Hodgkin’s disease; HCL: hairy cell leukemia; PLL: prolymphocytic leukemia; 
(N)SCLC: (non) small cell lung cancer; TAA: tumor associated antigen; TfR: transferrin receptor;   
CSF: cerebrospinal fluid, PAP: pokeweed antiviral protein; RA: rheumatoid arthritis; SLE: systemic lupus 
erythematosus. 
2.1. Diphtheria Toxin Based Immunotoxins 
2.1.1. Diphtheria Toxin—Mechanism of Action  
Diphtheria toxin (DT), secreted by pathogenic strains of the bacterium Corynebacterium diphtheria, 
is the prototype for the family of ADP-ribosylating toxins. It belongs to a group of toxins called AB 
toxins that consist of two fragments (A and B). The B fragment is responsible for cell entry (binding to 
a cell surface receptor and subsequent translocation into the cell cytoplasm) while the internalized A 
fragment intoxicates the cell by virtue of its enzymatic activity [119,120]. The toxin is secreted as a 
single protein of 535 amino acids and is composed of three functional domains: the N terminal domain 
(residues 1–193) represents the catalytic (C) A fragment/domain (DTA/DT-A). The C terminal portion 
of the toxin (amino acids 194–535) represents the B fragment and is divided into two functional 
domains: the translocation domain (T) (amino acids 202–378) and the receptor binding domain (R) 
(amino acids 386–535) [121]. The native diphtheria toxin binds, via its R domain, to heparin binding 
epidermal growth factor precursor on the cell membrane, where it is cleaved by cell-surface furin or Toxins 2010, 2  
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furin-like protease  [122,123]. The di-chain protein that is still linked by a single disulﬁde bond 
between cysteine 186 and cysteine 201 is internalized into clathrin coated pits and reaches the lumen 
of a developing endosome (where furin-mediated cleavage of toxin molecules that escaped cleavage 
by cell-surface proteases, may occur [122]). Upon endosome acidification, the T domain undergoes a 
conformational change that leads to exposure of hydrophobic areas that are inserted into the 
membrane, forming a channel through which the catalytic domain translocates and escapes from the 
endosome, probably with the aid of cytosolic factors [124–129]. In the cell cytoplasm, the catalytic 
domain exerts its toxic activity by transferring adenosine di-phosphate-ribose (ADP-ribose) moiety 
from nicotinamide dinucleotide (NAD) to a modified histidine
 residue (diphthamide) at position 715 in 
the eukaryotic translation elongation factor (eEF2). This action results in the inactivation of the latter, 
inhibition of protein synthesis, and programmed cell death  [13,130–133] (Figure 3). It was also 
reported that delivery of a single molecule of the catalytic domain into the cytosol is sufficient to kill a 
cell, demonstrating the extreme potency of this bacterial toxin [134].  
Figure 3. Main entry route and mechanism of action of diphtheria toxin. 1. The toxin is 
secreted as one polypeptide which is composed of three functional domains: the N terminal 
catalytic domain ((C), also referred to as DTA/DT-A), the translocation domain (T) and the 
receptor binding domain (R) (see 3D structure (PDB Entry: 1f0l). In the left panel, the 
colors of the subunits correspond to those in the scheme). In addition, a disulfide bond 
bridges the C and T domains; 2. The toxin binds via its R domain to a cellular receptor 
(heparin binding epidermal growth factor precursor); 3. Cell-surface furin protease cleaves 
the polypeptide chain between the C and T domains that remain linked by a disulfide bond; 
4. The toxin-receptor complex is internalized into clathrin coated pits; 5. In the lumen of 
the early endosome (EE), furin protease cleaves toxin molecules that escaped cell-surface 
cleavage. The T domain undergoes acidic-induced conformational change, inserted into the 
endosome membrane and forms a channel through which the catalytic domain can 
translocate into the cytoplasm where reduction of the interdomain bridging disulfide bond 
occurs; 6. In the cytoplasm, the catalytic domain inactivates eukaryotic translation 
elongation factor 2 (eEF2) by ADP-ribosylation, which causes translation inhibition and 
consequently cell death.  
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2.1.2. Targeting IL-2 Receptor: Denileukin Diftitox (Ontak) 
Denileukin Diftitox, which is also named “Ontak” or “DAB389 IL-2”, is a fusion protein designed 
to direct a truncated form of diphtheria toxin to cells that express the high-affinity IL-2 receptor, 
(consisting of the following subunits: CD25 (IL-2Rα),
 CD122 (IL-2Rβ), and CD132 (IL-2Rγ)), which 
is present in many different hematologic malignancies like adult T cell leukemia (ATL), chronic 
lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s lymphomas, cutaneous T cell lymphoma 
(CTCL) and other leukemias and lymphomas  [10,135–139]. The immunotoxin is comprised of a 
genetic fusion between a truncated form of DT (first 388 amino acids, “DAB389”), in which the natural 
receptor binding domain of the toxin was replaced by the cytokine interleukin-2 (IL-2) [140]. Phase I 
testing was conducted on patients with T-cell lymphoma (CTCL) (n = 35), other non-Hodgkin's 
lymphomas (NHL) (= 17), or Hodgkin's disease (HD) (n = 21). The drug, which was administrated by 
intravenous infusion, produced five complete (CR) and eight partial (PR) remissions in patients with 
CTCL with one CR and two PR occurring in NHL. No response was documented in patients with HD. 
The dose-limiting toxicity in these trials was asthenia  [141]. In the pivotal phase III trial, 30% 
of 71 patients with CTCL treated with
 Denileukin Diftitox had an objective response (20% partial 
response;
 10% complete response) [18]. since the FDA approval of ONTAK as the first immunotoxin 
for treatment of advanced CTCL in 1999, the drug was tested for treatment of other malignant and 
non-malignant diseases like B-cell NHL  [23], B-cell chronic lymphocytic leukemia (CCL)  [19] 
panniculitic lymphoma  [142], psoriasis  [17,143] and Graft-versus-host disease (GVHD)  [21]. 
Responses were observed in all of these trials. 
2.1.3. Targeting Granulocyte-Macrophage Colony Stimulating Factor Receptor: DT388-GM-CSF 
The majority of acute myeloid leukemia (AML) blast cells express the granulocyte-macrophage 
colony-stimulating factor (GM-CSF) receptor [144]. In order to target these cancerous cells, the human 
GM-CSF was fused to DT388, a truncated DT toxin, replacing its natural receptor binding 
domain [145,146]. The resulting molecule, DT388-GM-CSF (DTGM), was tested on 31 patients who 
were resistant to chemotherapy. Among them, one had a complete remission and two had partial 
remissions following treatment with the drug that was administrated by intravenous (i.v.) infusion. 
Liver failure or transient hepatic encephalopathy were observed in two patients, possibly as a result of 
inflammatory cytokine release from liver Kupffer cells (DT388-GM-CSF does not directly bind or 
damage hepatocytes) [35].  
2.1.4. Targeting Transferrin Receptor: Tf-CRM107 (TransMID) 
Transferrin receptors (TfRs) are overexpressed on rapidly dividing cells and various tumor cells. 
While relatively scarce in healthy brain tissue, intense expression of TfRs can be found on tumor cells 
of glioblastoma multiforme (GBM's)  [147]. Tf-CRM107, which is also called “transMID” is a 
conjugate protein of a mutant diphtheria toxin that lacks receptor-binding activity (CRM107) [148], 
linked by a thioester bond to human transferrin (Tf) [149]. In Phase I clinical trials, TF-CRM107 was 
delivered by high-flow interstitial microinfusion into the tumor region and reduction in tumor volume 
occurred in nine of 15 patients who could be evaluated, including two complete responses. No Toxins 2010, 2  
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symptomatic systemic toxicity occurred [32]. In the phase II clinical study, Tf-CRM107 treatment 
resulted in a 35% response rate: Of the 34 patients evaluable for efficacy, there were a total of five 
complete responders and seven partial responders. Infusions of Tf-CRM107 resulted in symptomatic 
progressive cerebral edema in eight of the total enrolled 44 patients (14%) that were responsive to 
medical management. Seizures were seen in three patients who responded to anticonvulsant 
therapy [33]. However, a conditional power analysis in phase III determined that Tf-CRM107 was 
unlikely to improve overall patient survival compared with the current standard of care, and it was 
decided to terminate the trial and further clinical development of the drug [34]. 
2.2. Pseudomonas Exotoxin A Based Immunotoxins 
2.2.1. Pseudomonas Exotoxin A—Mechanism of Action 
Pseudomonas exotoxin A (abbreviated as PE or ETA) is a 613 amino acid polypeptide secreted by 
the bacterium Pseudomonas aeruginosa as one of its virulence factors [150]. Like diphtheria toxin, it 
belongs to the family of ADP-ribosylating toxins [151] and to the group of AB toxins (see description 
of diphtheria toxin above). The toxin can be divided into three main structural and functional domains: 
The N-terminal domain Ia (aa 1–252) is responsible for cell recognition. Domain II (aa 253–364) is 
required for the translocation of the toxin across cellular membranes. The exact function of the 
structural domain Ib (aa 365–404) is not fully understood. The last four residues (aa 400–404) of 
domain Ib together with domain III (aa 405–613) form the catalytic subunit of the protein [152,153]. 
After the C-terminal Lysine 613 is removed by a plasma carboxypeptidase [154], leaving the terminus 
REDL, the toxin binds via its cell-binding domain Ia to CD91, also called alpha2-macroglobulin 
receptor/low-density lipoprotein receptor-related protein (α2MR/LRP), on the surface of the cell [155]. 
The toxin is then internalized and enters early endosomes mainly via clathrin-coated pits, but also via 
caveosomes, following association with detergent-resistant microdomains  [155,156]. In the acidic 
environment of the endosome, PE dissociates from its receptor, undergoes a conformational change, 
and is cleaved by the cellular protease furin in a furin-sensitive loop in domain II of the 
toxin  [123,157,158]. Following reduction of the single disulfide bond which holds the proteolytic 
fragments together [159], the enzymatic active C’ 37 kDa fragment travel in a Rab9-dependent route to 
the trans-Golgi network (TGN) [160]. There, its C terminal exposed KDEL-like sequence (REDL) 
binds the KDEL intracellular sorting receptor and the fragment travels to the endoplasmic reticulum 
(ER)  [161–163]. Alternatively, lipid sorting to the ER may occur  [156]. In the ER, sequences in 
translocation domain II mediates the translocation of the 37 kDa fragment to the cytoplasm in a 
process that probably involves the subversion of the ER-associated degradation (ERAD) pathway and 
a retrograde transport via the Sec61p translocon. Escaping, at least in part, from proteosomal 
degradation may be attributed to the low lysine content of the enzymatically active C terminal 37 kDa 
fragment [164–169]. In the cytosol, the APD-ribosylation enzymatic activity of domain III inactivates 
eEF-2 in a similar way to that of diphtheria toxin (see above), leading to protein synthesis inhibition 
and programmed cell death [130,132,170–173] (Figure 4).  Toxins 2010, 2  
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Figure 4. Main entry route and mechanism of action of Pseudomonas exotoxin A. 1. The 
secreted pseudomonas exotoxin A (PE) toxin can be divided into three main structural and 
functional domains: the N terminal receptor (R) binding domain I, translocation (T) 
domain II and the catalytic (C) domain III (see 3D structure (PDB Entry: 1ikq). In the left 
panel, the colors of the subunits correspond to those in the scheme. For the sake of 
simplicity, translocation domain II was extended to contain subdomain Ib). A single 
disulfide bond bridges between cysteines 265 and 287 within domain II; 2. Following 
removal of a C terminal lysine residue by plasma carboxipeptidase, the toxin binds to its 
cell-surface receptor (CD91, also called α2MR/LRP); 3. The toxin is internalized mainly 
via clathrin-coated pits; 4. In the early endosome (EE), the toxin undergoes conformational 
change and is cleaved by the protease furin in a furin sensitive loop, in domain II. The two 
cleavage products remain linked by the intradomain disulfide bond; 5. Following reduction 
of the disulfide bond, the enzymatically active C terminal fragment, which is composed of 
domain III and about two thirds of domain II, is routed to the trans-Golgi network where it 
binds via its C terminally exposed REDL sequence to KDEL receptor and travels to the 
endoplasmic reticulum (ER); 6. In the ER, sequences in domain II mediate the 
retro-translocation of the polypeptide via the Sec61p translocon into the cytoplasm;   
7. The catalytic domain inactivates eukaryotic translation elongation factor 2 (eEF2) by 
ADP-ribosylation, which causes translation inhibition and consequently cell death.  
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2.2.2. Targeting the CD25 Subunit of IL2-Receptor: LMB-2 
For the construction of PE-based immunotoxins, the receptor binding domain Ia can be replaced by 
an antibody, antibody derivative, or a ligand, which preferentially binds to tumor-associated 
antigen/receptor. The resulting truncated form of PE is designated PE40, indicating its molecular 
weight (40 kDa). In addition, a large part of domain Ib can be deleted without effecting cytotoxicity, 
generating a smaller form of the modified toxin, which is denoted PE38 (38 kDa).  
In order to target CD25 expressing cells (low-affinity IL2 receptor, see above) regardless of the 
presence of other IL2R subunits (CD25 is generally expressed to a much greater extent relative to Toxins 2010, 2  
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CD122 and CD132 on most malignant cell types [137,138]), PE38 was fused to a single-chain form of 
the anti-CD25 monoclonal antibody anti-Tac  [174–176]. The resulting immunotoxin, 
Anti-TacFv-PE38 (LMB-2), demonstrated promising results in pre-clinical trials toward CD25
+ cells 
and tumor xenografts in nude mice  [177–179]. In a Phase I trial, LMB-2 was administrated 
intravenously to 35 patients with chemotherapy-resistant leukemia, lymphoma and HD, resulting   
in 1/35 (3%) complete and 7/35 (20%) partial remissions. The most common toxicities included 
transaminase elevations that were associated with fever, possibly as an outcome of cytokine release. 
Six of the 35 patients made neutralizing antibodies after one cycle, preventing them from receiving 
re-treatment  [180–182]. In Phase II trials on patients with metastatic melanoma, administration of 
LMB-2 has led to a transient partial reduction in circulating and tumor-infiltrating CD25
+ 
T-regulatory  (Treg) cells which are able to suppress the ability to vaccinate against self/tumor 
antigens  [183]. However, LMB-2 therapy did not augment the immune response to peptide based 
cancer vaccines [184]. Other Phase II trials are currently underway in patients with CD25
+ Chronic 
Lymphocytic Leukemia (CLL), Cutaneous T cell lymphoma (CTCL) and Hairy Cell Leukemia (HCL). 
2.2.3. Targeting CD22: BL22 
CD22 is a 135-kDa phosphoglycoprotein adhesion molecule present on the surface of B cells, 
including human B-cell lymphomas and leukemias [185–189]. RFB4(dsFv)-PE38 (BL22) is a stable 
immunotoxin targeted against CD22 expressing cells, and is composed of disulfide stabilized Fv 
regions (dsFv) of the anti-CD22 monoclonal antibody RFB4 [190] fused to PE38 [191]. Clinical trials 
with i.v. administrated BL22 in adults with hairy cell leukemia resistant to purine analogue therapy, 
produced promising results with 19 complete remissions (61%) and six partial responses (19%) in 31 
patients in Phase I  [45], and 25% complete remission, 25% partial response after one cycle of 
treatment in Phase II (n = 36) [46]. The most common toxicities included hypoalbuminemia, 
transaminase elevations, fatigue, edema and reversible grade 3 hemolytic uremic syndrome, not 
requiring plasmapheresis. A recent Phase I clinical trial that was conducted for pediatric subjects with 
CD22
+ ALL and non–Hodgkin lymphoma [47] showed that the treatment was associated with an 
acceptable safety profile and adverse events were rapidly reversible. No maximum tolerated dose was 
defined, and although no responses were observed, transient clinical activity was seen in most 
subjects  [192–194].  
2.2.4. Targeting the Le
Y Antigen: LMB-1 
Lewis Y (Le
Y), a type 2 blood group related oncofetal carbohydrate antigen is expressed on 
nearly  70% of human epithelial carcinomas  [195–197]. The LMB-1 immunotoxin consists of the 
anti-Lewis Y monoclonal antibody B3  [198] conjugated to PE38. In a Phase I clinical trial, the 
immunotoxin was tested on 38 patients with Le
Y expressing carcinomas of breast, ovarian, colon, 
esophagus, stomach and ampulla of Vater. A complete remission was observed in a patient with 
metastatic breast cancer and a greater than 75% tumor reduction was observed in a colon cancer 
patient following systemic administration of the immunotoxin. The major toxicity was vascular leak 
syndrome ascribed to endothelial damage, probably due to binding of the B3 antibody to Le
Y antigen 
which is present in small amounts on endothelial cells [199]. Later developments of Lewis Y targeted Toxins 2010, 2  
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toxins produced the recombinant immunotoxins B3(Fv)-PE38 (LMB-7), B3(dsFv)-PE38 (LMB-9) and 
BR96-Fv-PE40 (SGN-10) which were clinically evaluated in patients with Lewis Y-expressing 
malignancies. However, no significant antitumor activity was observed in these trials [10,200].  
2.3. Ribosome Inactivating Proteins Based Immunotoxins 
2.3.1. Ribosome Inactivating Proteins—Mechanism of Action  
Ribosome inactivating proteins (RIPs) are a group of glycosylated and non-glycosylated enzymes 
with N-glycosidase activity that were initially detected in higher plants, but have also been found in 
fungi, algae and bacteria (for comprehensive reviews, see [201–207]). RIPs may be present in one or 
more tissues of the plant, and their expression is enhanced in senescence and under various stress 
conditions [208–214] including microorganisms and viral infections [215–217]. RIPs are artificially 
divided into three groups on the basis of their structure and mode of activation: type I RIPs are single 
chain basic proteins of about 30 kDa with enzymatic activity. Some well known members of this group 
are saporin (from Saponaria officinalis), pokeweed antiviral protein (PAP) (Phytolacca americana) 
and gelonin (Gelonium multiforum). Type II RIPs, like ricin (from Ricinus communis) and abrin 
(Abrus precatorius), are heterodimeric proteins consisting of an enzymatically active A chain of   
about 30 kDa linked through a disulfide bond to a B chain of approximately 35 kDa which has the 
properties of a lectin. Type III RIPs, like the maize and the barley proteins b-32 and JIP60, 
respectively, are synthesized as inactive precursors (proRIPs), which lacks a lectin moiety and are 
activated by proteolytic processing which includes the removal of terminal sequences and a short 
inhibitory internal peptide [201,206–208,218–220]. 
Ricin, the prototype of type II RIPs, is a glycosylated heterodimer that binds through its lectin 
B-chain to galactose or N-acetylgalactosamine residues on glycoproteins and glycolipids which are 
present on the surface of most eukaryotic cells [221–226]. In addition, certain cells like macrophages 
and rat liver endothelial cells that express surface mannose receptors were demonstrated to bind ricin 
also through its own oligosaccharide side chains  [227–232]. The cell surface-bound ricin is 
internalized by clathrin-dependent as well as clathrin-independent endocytosis and travels backward 
from the Golgi to the ER, where its disulfide linked chains are separated by protein disulfide 
isomerase. As in the case of PE, ricin is thought to subvert the ERAD pathway, exploiting it for the 
retrograde transport of the enzymatically active A chain (RTA) into the cell cytosol through the 
Sec61p translocon. Because of its paucity of lysines, RTA may escape, at least in part, degradation by 
the proteosome [167,169,233–242] (Figure 5). Type I and type III RIPs lack the cell-binding lectin B 
chain and are thus generally much less toxic than type II RIPs. However, like ricin, some glycosylated 
type I RIPs may bind to carbohydrate receptors on the cell surface, and binding of type I RIPs to low 
density lipoprotein (LDL) receptor related protein (α2MR/LRP), (which also binds PE) has also been 
demonstrated [243–245]. In addition, coupling type I RIPs (which are equivalent to the enzymatically 
active A chain of type II RIPs) to a carrier that is capable of binding cells renders the conjugate highly 
cytotoxic [206,246–249]. The specific mechanism by which type I RIPs gain entry into the cell cytosol 
remains unclear, but is probably different from that of type II RIPs like ricin: Experiments with the 
type I RIP, saporin, indicated that it does not rely on Golgi-mediated retrograde transport and ERAD 
and may involve toxin translocation to the cytoplasm from the endosomes [242,250].  Toxins 2010, 2  
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Figure 5. Main entry route and mechanism of action of ricin. 1. Ricin toxin is translated as 
a single glycosylated polypeptide that is composed of a catalytic A domain and a lectin B 
domain (see 3D structure (PDB Entry: 2aai) in the left panel; the colors of the subunits 
correspond to those in the scheme). In the producing plant, a small peptide that links the A 
and B domains is removed, and the A and B chains remain associated via a single disulfide 
bond; 2. The toxin binds through the lectin B chain to cell-surface galactose or 
N-acetylgalactosamine residues on glycoproteins and glycolipids; 3. Cell-surface bound 
ricin is internalized by clathrin-dependent as well as clathrin-independent endocytosis and 
reaches the early endosome (EE); 4. The toxin travels backward through the Golgi to the 
endoplasmic reticulum (ER), where its’ disulfide linked chains are separated; 5. The 
catalytic A chain (RTA) is retro-translocated via the Sec61p translocon into the cytoplasm; 
6. The catalytically active RTA irreversibly damages ribosome by removing a specific 
adenine from a conserved 28S rRNA loop (“sarcin/ricin loop”–SRL), which causes 
translation inhibition and consequently cell death. 
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Once in the cytosol, the enzymatic moiety of RIPs irreversibly damages ribosomes by removing a 
specific adenine (corresponding to residue A4324 in rat 28S rRNA) from a GAGA sequence in a 
conserved 28S rRNA loop, the so called “sarcin/ricin loop” [251–253]. This modification renders the 
ribosome unable to interact with elongation factors 2 (eEF2), resulting in inhibition of translation and 
ultimately apoptotic cell death  [201,254–264]. In addition to their classical ribosome-inactivating 
glycosidase activity, other activities and enzymatic properties were associated with RIPs: antiviral 
activity [265], depurination of (non-ribosomal) RNA and adenine DNA glycosylase activity [266–270], 
deoxyribonuclease activity  [271–278], ribonuclease activity  [279,280], removal of adenine from 
poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase (an enzyme involved in DNA repair) [281,282], 
depurination of the capped RNA template [283,284], superoxide dismutase (SOD) activity [285–287] 
and phospholipase activities  [288]. The involvement of these non-classical RIP activities in 
cytotoxicity is debatable, though accumulating evidence suggests that ribosome inactivation is not the 
sole means by which RIPs execute their toxic effects [264,289–295].  Toxins 2010, 2  
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2.3.2. Targeting CD25 and CD30: RFT5-dgA and ki-4.dgA. 
CD25 and CD30 are lymphoid activation markers which are highly expressed on the surface of 
Hodgkin's lymphoma cells and only present on a minority of normal human cells [135,296–298]. In 
order to target these cells, two immunotoxins, RFT5-dgA (IMTOX25) and ki-4.dgA, were constructed. 
The toxic moiety in these immunotoxins was a chemically deglycosylated form of ricin A chain (dgA) 
(deglycosylation was demonstrated to minimize nonspecific carbohydrate-receptors mediated uptake 
of RTA based immunotoxins by reticuloendothelial cells in the liver [299–305]) linked to the targeting 
moieties RFT5 (anti-CD25) and ki-4 (anti-CD30) monoclonal antibodies, respectively. Phase I/II trials 
with i.v. administrated RFT5-dgA on 18 patients with refractory Hodgkin's disease (HD), resulted in 
two partial remissions (PR), one minor response (MR) and five stable diseases (SD) [75]. In a Phase I 
study of Ki-4-dgA on 15 patients, one PR, one MR and two SD were observed. Dose-limiting 
toxicities were related to vascular leak syndrome, consisting of edema, tachycardia, dyspnea, weakness 
and myalgia  [75]. A Phase II study evaluating the side effects and efficiency of RFT5-dgA 
(IMTOX25) treatment in patients with relapsed or refractory cutaneous T-cell non-Hodgkin lymphoma 
(CTCL) was completed recently, and the immunotoxin is currently evaluated as a treatment for 
metastatic melanoma (http://clinicaltrials.gov/).  
2.3.3. Targeting CD22 and CD19: RFB4-dgA and HD37-dgA 
CD22 and CD19 are cell surface glycoproteins expressed on normal and malignant B cells [306–309]. 
For targeting B-cell lymphoma cells, the anti CD22 monoclonal antibody RFB4 [190,310] and the anti 
CD19 monoclonal antibody HD37 [311] were conjugated to dgA. In a Phase I clinical trial with the 
immunotoxin RFB4-dgA (IMTOX-22), five of 24 evaluable patients with B-cell lymphoma showed a 
partial response and one showed a complete response. Similar results were obtained when the drug was 
administrated as a continuous infusion instead of intermittent bolus [67,312]. Partial and complete 
responses were also obtained in a Phase I trial on patients with non-Hodgkin's B-cell lymphoma 
treated with the immunotoxin HD37-dgA (IMTOX-19) [69]. Vascular leak syndrome (VLS) was a 
common dose-related toxicity in these studies. 
3. Toxin Based Suicide Gene Therapy 
The delivery of genetic material into target cells for the purpose of gaining a therapeutic effect is 
generally known as “gene therapy” (for review, see  [313–323]). Advances in molecular biology, 
virology and nanotechnology in the past decade enabled the development of a variety of viral and 
non-viral gene delivery systems [324–326]. When the death of the target cell is the desired therapeutic 
outcome of the transgene delivery, the process is termed “suicide gene therapy” and involves delivery 
of genes whose products are either toxic, proapoptotic or have the ability to activate precursors of toxic 
drugs (“pordrugs”)  [327–331]. In order to minimize damage to healthy tissue, a specific targeting 
mechanism must be applied and transcriptional targeting is a very common strategy. The method is 
based on positioning the suicide gene to be transferred under the transcriptional regulation of a 
promoter/element which is specifically or at least preferentially active in the target tissue [332–338]. If 
transcription of a toxin encoding gene is controlled by such a target specific promoter, eradication of 
undesirable cell population is feasible with minimal collateral damage (Figure 1). The next chapter Toxins 2010, 2  
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reviews some of the prominent toxin-based suicide gene therapy studies and developments which are 
classified by their target disease; the majority of them were evaluated at a preclinical level and aimed 
at cancer therapy. Information about suicide gene constructs developed in these and other studies are 
summarized in Table 2. 
Table 2. Preclinically and clinically evaluated/under evaluation toxin-based suicide genes. 
Construct Name 
Transcription 
Regulatory Element 
Toxin  Delivery Vector Disease 
Clinical 
Trial Phase
Reference
Ad5-PSE/PSA-DT-A  PSA *  DTA  Adenovirus  Prostate cancer 
Preclinical 
phase 
 [339] 
Ad-PSA/FLP + 
Ad-
RSV/FRT2neo/DT-A 
PSA *  DTA  Adenovirus  Prostate cancer 
Preclinical 
phase 
 [340] 
C32-PSA/DT-A  PSA *  DTA  Cationic polymer Prostate cancer 
Preclinical 
phase 
 [341] 
pTHA-47, pTHA-49 
hCG (α or β 
subunits) * 
DTA 
Naked DNA- 
electroporation 
Ovarian cancer 
Preclinical 
phase 
 [342] 
pHE-4/DT-A, 
117-MSLN/DT-A 
HE4, MSLN *  DTA  Cationic polymer Ovarian cancer 
Preclinical 
phase 
 [343] 
DTA-H19 (BC-819)  H19 *  DTA 
Naked DNA, 
Cationic polymer
Ovarian, bladder, 
pancreatic 
cancers 
I/II, II   [344–346]
DTA-TER, 
DTA-TERT 
hTER,hTERT *  DTA 
Naked DNA- 
CaPO4 
precipitate 
Bladder cancer 
Preclinical 
phase 
 [347] 
HIV-DT-A 
HIV Tat and Rev cis-
acting responsive 
sequences 
DTA 
Retrovirus, 
cationic 
liposomes 
HIV-1 infection 
Preclinical 
phase 
 [348–350]
pNL-DTΔN-GFP-
RRE-SA 
HIV Rev cis-acting 
responsive sequence 
Attenuated 
DTA 
variant 
Non-integrating 
lentivirus 
HIV-1 infection 
Preclinical 
phase 
 [351] 
pA3–6PED 
PAX3 DNA 
responsive sequences 
DTA 
Cationic 
liposomes 
ARMS 
Preclinical 
phase 
 [352] 
petbz.ES.DT-A, 
pA.E-Sel.DT-A 
E-selectin *  DTA 
Naked DNA- 
electroporation 
Activated 
endothelial cells 
(Angiogenesis) 
Preclinical 
phase 
 [353] 
GH-loxP-DT + CMV-
Cre / GH-Cre 
 
Growth hormone 
(GH) * 
DTA  Adenovorus  Pituitary Tumor 
Preclinical 
phase 
 [354] 
BV-CG/ITR-DTA 
GFAP * + CMV 
enhancer + ITR of 
AAV 
DTA  Baculovirus  glioma 
Preclinical 
phase 
 [355] 
G1CEAPEANa, 
G1CEADTANa 
CEA *  PEA, DTA
Cationic 
liposomes 
Colorectal 
carcinoma 
Preclinical 
phase 
 [356] 
pRad51-DTA  Rad51 *  DTA 
Various 
transfection 
methods 
Variety of cancer 
cells 
Preclinical 
phase 
 [357] Toxins 2010, 2  
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Table 2. Cont. 
Construct Name 
Transcription 
Regulatory Element 
Toxin  Delivery Vector Disease 
Clinical 
Trial Phase
Reference
pAF-DTA, 
pAF5.1DTA 
AFP *  DTA 
Cationic 
liposomes 
HCC 
Preclinical 
phase 
 [358,359]
pTHA45, pTHA17 
Immunoglobulin 
heavy/κ-light chain * 
DTA 
Naked DNA- 
electroporation 
B-Lymphoid 
Cells 
Preclinical 
phase 
 [360] 
pTyrIII/DT-A, 
pMIA III/DT-A 
MIA, tyrosinase, *  DTA  Cationic lipids  Melanoma 
Preclinical 
phase 
 [361] 
retro-1.3MBPppe, 
retro-1.3MBPpri 
MBP *  PE/RTA  Retrovirus  Glioblastoma 
Preclinical 
phase 
 [362] 
pMSLN/DT-A  MSLN *  DTA  Cationic polymer Pancreatic cancer 
Preclinical 
phase 
 [363] 
V3  Hsp70B' * + HSEs 
DTA, 
attenuated 
DTA 
variants 
Cationic 
liposomes 
Pancreatic cancer 
Preclinical 
phase 
 [364] 
pLTR-DT 
p34 responsive 
sequences (BLV-
LTR) 
DTA 
Cationic 
liposomes 
BVL infected 
cells 
Preclinical 
phase 
(veterinary 
use) 
 [365,366]
Abbreviations: DTA/DT-A: the catalytic A fragment of diphtheria toxin; PSA: prostate-specific antigen; 
hCG: human chorionic gonadotropin; ARMS: alveolar rhabdomyosarcoma; GFAP: glial fibrillary acidic 
protein; ITR: inverted terminal repeats, AAV: adeno-associated virus; PEA: truncated form of pseudomonas 
exotoxin A (domains II+III); CEA: human carcinoembryonic antigen; HCC: Hepatocellular carcinoma; 
hTER: human telomerase RNA, hTERT: human telomerase reverse transcriptase; AFP: human alpha-
fetoprotein; MIA: Melanoma inhibitory activity; MBP: myelin basic protein; MSLN: Mesothelin; HSP: heat 
shock protein; HSEs: heat shock elements; hCG: human chorionic gonadotropin; CMV: cytomegalovirus; 
HIV: human immunodeficiency virus; LTR: long terminal repeat; BLV: Bovine leukemia  virus.   
* Refers to the name of the gene/gene product whose transcriptional regulatory elements were used to drive 
the expression of a toxic gene in target cells. 
3.1. Targeting Prostate Cancer  
Prostate cancer (PCA) is the most common cancer diagnosed in men and a leading cause of cancer 
deaths  [367]. Normal and malignant prostate epithelia specifically express the kallikrein protease 
prostate-specific antigen (PSA), a serine protease with trypsin- and chymotrypsin-like activities that is 
responsible for liquifaction of semen [368,369]. PSA gene regulatory regions are prime candidates to 
direct prostate-specific expression [370–373]. When placed under the transcriptional regulation of the 
PSA promoter, the diphtheria toxin A chain (DT-A) encoding gene which was delivered by an 
adenoviral vector showed strong inhibition of tumor growth in a PSA-producing prostate tumor 
xenograft mouse model while not affecting non-PSA producing tumor xenografts  [339]. A PSA 
promoter-based lentiviral vector has also been used as a mean for DT-A gene delivery, leading to 
specific eradication of prostate tumor xenografts in nude mice following a single intratumoral 
injection. Repetitive injections were shown to inhibit the growth of recurrent tumors [374].  Toxins 2010, 2  
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In another study, a nanoparticulate system based on the cationic poly(b-amino ester)polymer, 
C32 [375], was used as a DNA delivery system of a suicide gene encoding for a diphtheria toxin A 
chain (DT-A) under the transcriptional regulation of a prostate-specific modified human PSA 
promoter, PSE-BC [371]. The genetic material/cationic polymer complex was locally delivered into 
normal prostate and prostate tumors in mice, causing massive apoptotic prostate cell death, without 
damaging surrounding tissue [341].  
In order to gain tighter control on the expression of the very potent DT-A toxin, Peng et al [340] 
utilized a dual expression controlling system that relies both on transcriptional regulation and DNA 
recombination  [376–378]. On the basis of their system, the chimeric modified enhancer/promoter 
sequence of the human prostate-specific antigen (PSA) gene, PSE-BC [371], was used to regulate the 
expression of the Saccharomyces cerevisiae 2µ plasmid derived site-directed FLP recombinase. When 
prostate specific expression of FLP recombinase occurs, site directed DNA recombination that leads to 
DT-A gene expression takes place. The investigators showed eradication of PSA-expressing normal 
prostate cells and prostate cancer cells in culture, in xenografts and in a transgenic mouse model 
following adenoviral delivery of DNA encoding the prostate specific promoter-driven Flp recombinase 
and the Flp-responsive DT-A gene. Furthermore, Flp recombinase expression was shown to be 
regulated in a manner that correlates with the amount of PSA expression in these cells [340]. 
3.2. Targeting Ovarian Cancer  
Ovarian cancer is a common malignancy in women, and causes more deaths than any other type of 
female reproductive tract cancer [379]. Lidor et al [342] have demonstrated specific protein synthesis 
inhibition in malignant ovarian cell lines transfected with plasmids encoding transcriptionally 
regulated diphtheria DT-A. The toxic gene transcription was regulated by elements of the human 
chorionic gonadotropin (hCG) promoter, a heterodimeric glycoprotein placental hormone involved in 
different pregnancy-promoting processes. Although principally produced by trophoblasts, hCG is also 
expressed in some malignant tumors of the ovary, uterus, testis, colon, liver, pancreas lung, and 
stomach [380–382].  
Targeted expression of DT-A in ovarian cancer cells in vitro and in tumor cells in mouse models 
was performed by Huang et al  [343] using poly(h-amino ester) polymers as a vector for 
nanoparticulate delivery of DNA. In these ovarian-specific antitumor constructs, the promoters of two 
genes, HE4 (WFDC2) and MSLN (which transcriptional activity is significantly enhanced in ovarian 
cancer cells relative to normal ovarian cells and cells in other tissues [383–389]) were chosen to target 
the expression of DT-A gene to ovarian tumor cells. Significant reduction in tumor mass and a 
prolonged life span of xenografts bearing mice were observed as a result of DT-A nanoparticles 
administration directly to subcutaneous xenograft tumors and to the peritoneal cavity. Moreover, 
treatment with DT-A nanoparticles resulted in more efficient suppression of tumor growth compared 
to clinically relevant doses of the standard chemotherapeutics cisplatin and paclitaxel, with minimal 
nonspecific tissue and blood chemistry toxicity [343].  
Recently, Mizrahi et al [345] reported the use of transcriptional regulatory sequences of the H19 
gene to drive the expression of DT-A specifically in ovarian tumor cells. H19 is a paternally imprinted, 
maternally expressed, oncofetal gene that encodes an RNA acting as "riboregulator" without a protein 
product. It is expressed at substantial levels in several different human tumor types, including Toxins 2010, 2  
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epithelial ovarian cancer  [390], but is only marginally or not at all expressed in normal adult 
tissues  [391–399]. Cationic polymer PEI based delivery of DTA-H19 plasmid, encoding the toxic 
DT-A transcriptionally controlled by regulatory sequences of the H19 gene, showed high killing 
potential in ovarian cancer cell lines and a significant tumor growth inhibition in animals [345]. In a 
later case study, DTA-H19 plasmid that was intraperitoneally injected into the peritoneum of a woman 
with advanced and recurrent ovarian carcinoma has been reported to yield a complete resolution of 
ascites following several infusions, with minimum adverse events [346]. Phase I/II study of DTA-H19 
administered intraperitoneally in subjects with advanced stage ovarian cancer with evidence of 
symptomatic ascites is currently ongoing. 
3.3. Targeting Bladder Cancer  
Bladder cancer is the second most common urologic malignancy after prostate cancer. It is 
estimated that bladder cancer will account for 70,530 new cases of cancer and 14,680 cancer-related 
deaths in the United States during 2010 [400,401]. One of the most crucial enzymes in cell immortality 
and cancer is telomerase which maintains telomere length stability in almost all cancer cells [402]. 
Essential conserved core components of the human telomerase include the reverse transcriptase protein 
family member hTERT and the telomerase RNA hTER [403]. Following in situ hybridization analysis 
that showed high levels of hTER and hTERT expression in bladder tumors (while no signal was 
detected in normal tissue), transcription regulatory elements of these two genes were used for targeted 
gene therapy purpose by driving the expression of the toxic DT-A gene in bladder cancer cells. 
Experimental data demonstrated that transfection of bladder and hepatocarcinoma cell lines with DT-A 
expression plasmids under the control of hTER or hTERT regulatory elements resulted in cytotoxicity 
in accordance with the relative activity of these promoter elements in these cells [347]. 
In another study, expression of DT-A in subcutaneous injected syngeneic bladder tumor cell lines in 
mice was driven by the previously described H19 gene regulatory sequence (which is expressed in 
tumors derived from tissues (such as bladder) that exhibited the gene during embryonic 
development  [404]). Intratumoral injection of the DNA vector as a calcium phosphate precipitate 
caused a significant suppression of subcutaneous tumor growth, with no obvious toxicity toward the 
host [405]. Significant suppression of tumor growth in animals and nearly complete ablation of the 
tumor in two human patients was also reported by the same group following intravesicle (into the 
bladder) administration of the DTA-H19 vector (which also showed high killing potential in ovarian 
cancer cells, see above) complexed with the transfection enhancer reagent Jet-PEI. No apparent 
toxicity toward the host was observed [406]. Phase I/II clinical studies in 18 patients with H19 over 
expressing superficial bladder cancer showed 22% complete response and 44% complete marker tumor 
ablation or a 50% reduction of the marker lesion after six treatments in which the DTA-H19 (BC-819) 
vector was administrated intravesically as a complex with polyethyleneimine. No dose limiting 
toxicity was observed and the most frequent adverse events were mild to moderate bladder discomfort, 
dysuria, micturition urgency, urinary tract infection, diarrhea, hypertension and asthenia [344]. 
3.4. Targeting Viral Infected Cells  
HIV-1, the main cause of acquired immune deficiency syndrome (AIDS), has been the most studied 
infectious agent in the last 30 years. The HIV retroviral genome carries six regulatory genes, including Toxins 2010, 2  
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Tat, Rev, Vpr, Vif, Vpu, and Nef. Of these genes, Tat encodes a protein that plays key roles in 
controlling productive and processive viral gene transcription. The Tat protein binds to the specific 
sequences of TAR (Transactivation Response Element) located in the 5’ LTR, one of two terminal 
repeated segments of the viral genome, and exerts its effect by increasing the rate of transcription of 
the nascent HIV RNA. The viral Rev protein was found to be required for expression of the viral late 
gene products. By binding to a secondary RNA structure, the Rev-responsive element (RRE), the Rev 
protein tethers partially spliced and unspliced viral RNAs encoding the late viral proteins to the 
cellular CRM-1-mediated nuclear-export pathway, leading to enhanced cytoplasmic levels of these 
RNAs and increased expression of the encoded proteins [407–412]. Applying the knowledge about 
these viral molecular mechanisms for regulated gene expression, Harrison et al. have demonstrated the 
use of a combination of Tat and Rev cis-acting responsive sequences for achieving enhanced 
expression of transgenes in cells expressing both regulatory trans-acting Tat and Rev proteins; while 
maintaining low basal expression in naive cells  [413]. Substantially impaired HIV production, 
following HIV proviral DNA transfection of HeLa cells containing integrated HIV-regulated (Tat-Rev 
responsive) DT-A gene, was shown in a subsequent study  [414]. A T-Cell line (H9) that was 
transduced with a recombinant retroviral vector encoding HIV regulated wild-type or attenuated DT-A 
gene also showed substantially long-term impaired ability to produce HIV virions upon transfection 
with proviral DNA or infection with laboratory or clinical HIV strains [348,415]. Using the same 
construct, significant protection against HIV infection (dependent both on the stock of HIV-1 used and 
on the dose) was also observed in the U937 cell line which exhibits many of the characteristics of 
tissue monocytes that serve as an important reservoir for the virus in vivo [349,416]. It was later 
reported that co-transfection of the HIV regulated DT-A construct (HIV-DT-A) with an HIV proviral 
DNA using cationic liposome-mediated gene delivery (“lipofection”) could prevent virus production in 
HeLa cells. However, although HIV-regulated genes were found to be expressed when transfected into 
chronically HIV infected cells, transfection with HIV-DT-A did not significantly reduce virus 
production in an already chronically or de novo HIV-infected cell population, probably due to the low 
percentage (~5%) of “lipofected” cells [350]. 
4. Protease Activated Toxins 
4.1. Extracellular Protease Activated Toxins 
Cytotoxic activity of PE, DT and other bacterial toxins (like the anthrax toxin that will be described 
in the following section) depends on a proteolytic cleavage taking place in an early step of the 
intoxication process [122,123,157,158,417–420]. Since different disease-related cells are sometimes 
associated with a distinguished extracellular proteolytic activity, as will be discussed shortly, it is 
conceivable that replacing the natural cleavage site of a toxin with that of a disease-related protease 
may confer the new molecule with the ability to specifically eradicate disease-related cells (Figure 1). 
Several studies in which such molecules have been developed and preclinically evaluated, classified 
by their targets, are described in the following chapter. Information about the reviewed and other 
extracellular activated toxins is summarized in Table 3. Toxins 2010, 2  
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Table 3. Preclinically Evaluated/under Evaluation Protease Activated Toxins. 
Construct  
Name 
Activating 
Protease 
Protease 
Localization 
Components 
Toxin 
Source 
Activation 
Mode 
Target References
PA-L1/L2 + 
FP59 
MMPs 
(mainly 
MMP2 and 
MMP9) 
Extracellular 
PA (modified) 
+FP59 
Anthrax + 
PE 
Binding and 
translocation of 
the toxic moiety 
MMPs 
expressing 
tumor cells 
 [421] 
PA-L1 + LF 
MMPs 
(mainly 
MMP2 and 
MMP9) 
Extracellular 
PA (modified) 
+LF 
Anthrax 
Binding and 
translocation of 
the toxic moiety 
Tumor 
vasculature; 
MMPs 
expressing 
tumor cells 
with V600E B-
Raf mutation 
 [422–424] 
PrAg-U2 + 
FP59 
uPA Extracellular 
PA (modified) 
+FP59 
Anthrax + 
PE 
Binding and 
translocation of 
the toxic moiety 
Tumor cells 
with receptor-
associated uPA 
activity 
 [425–429] 
PrAg-L1-I210A 
+ PrAg-U2 
R200A + FP59 
MMPs 
+ uPA 
(both 
required) 
Extracellular 
PA (modified) 
+FP59 
Anthrax + 
PE 
Binding and 
translocation of 
the toxic moiety 
MMPs 
expressing 
tumor cells 
with receptor-
associated uPA 
activity 
 [430] 
UFT3  PSA 
Extracellular 
and 
intracellular 
Ubiquitin 
(mutant), 
saporin 
Saporin 
Toxin 
stabilization 
Prostate cancer 
cells 
 [431] 
DTU2GMCSF  uPA Extracellular 
DT388 
(modified), 
GM-CSF 
DT 
Translocation of 
the toxic moiety 
AML cells 
(the toxin is 
targeted also by 
fusion to  
GM-CSF) 
 [432] 
FLD/MM, 
FLD/YV 
HIV-1 
protease 
Intracellular  PA + LFN-DTA
Anthrax + 
DT 
Toxin 
stabilization 
HIV-1 infected 
cells 
 [433] 
TAT-Pro-HIV-
p2/NC, TAT-
Pro-HIV-
MA/CA 
HIV-1 
protease 
Intracellular 
HIV-1 TAT 
transduction 
peptide, Maize 
RIP (modified) 
Maize 
RIP 
Enhancement in 
the enzymatic 
activity of the 
toxic moiety 
HIV-1 infected 
cells 
 [434] 
Abbreviations: PE: pseudomonas exotoxin A; DT: diphtheria toxin; DTA/DT-A: the catalytic A fragment of 
diphtheria toxin; DT388: truncated form of DT; MMPs: matrix metalloproteinases; RIP: ribosome inactivating 
protein; PA/PrAg: anthrax protective antigen; FP59: anthrax toxin lethal factor residues 1–254 fused to the 
ADP-ribosylation domain of PE; PA: anthrax toxin protective antigen; LF: anthrax toxin lethal factor; uPA: 
urokinase plasminogen activator; NSCLC: non–small cell lung cancer; PSA: prostate-specific antigen; HIV: 
human immunodeficiency virus; AML: acute myeloid leukemia; GM-CSF: granulocyte macrophage   
colony-stimulating factor, LFN: amino acids 1-255 of anthrax toxin lethal factor. Toxins 2010, 2  
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4.1.1. Targeting Matrix Metalloproteinases (MMPs) Overexpressing Tumor Cells 
Matrix metalloproteases (MMPs) are a multigene family of zinc-dependent endopeptidases, which 
are secreted as latent pro-enzymes and have the capacity to degrade components of the extracellular 
matrix (ECM) following activating cleavage. In addition, MMPs have the ability to process molecules 
such as growth factors, receptors, adhesion molecules, other proteinases and proteinase inhibitors. 
MMPs are basically divided into distinct subclasses according to their substrate specificity and cellular 
localization: the secreted soluble collagenases, gelatinases, stromelysins and matrilysins; and the 
membrane-type MMPs which are integral plasma membrane proteins capable of activating MMPs. For 
certain family members, including some of the membrane-associated MMPs, activating cleavage can 
be achieved intracellularly by the protease furin. For other MMPs, however, activation is executed by 
extracellular proteases such as plasmin or other MMPs. While restricted to only a small number of 
normal cells, several MMPs are overexpressed by different kinds of solid tumors and have been 
implicated in the ECM degradation associated with tumor growth, angiogenesis and 
invasiveness [435–439].  
Anthrax toxin (AnTx) is a major virulence factor secreted by the gram-positive, spore-forming 
bacterium Bacillus anthrachis. The toxin, which damages cells and impairs host defenses, belongs to a 
family of toxins called “binary toxins” which are characterized by consisting of minimally two discrete 
nontoxic proteins that must be combined to elicit toxicity. AnTx consist of three non-toxic 
plasmid-encoded multidomain proteins: protective antigen (PA/PrAg; 83 kDa), lethal factor   
(LF; 90 kDa) and edema factor (EF; 89 kDa) (for review, see [440–442]). Intoxication begins with the 
binding of PA to either of its two known cellular receptors ATR/TEM8 [443] and CMG2 [444]. PA 
then undergoes an activating cleavage by a member of the furin family of cellular proteases [418,420], 
into an N terminal PA63 (63 kDa) and C terminal PA20 (20 kDa) fragments. Following cleavage, 
receptor-bound PA63 self associate to form a ring-shaped homoheptamer [445], called the prepore, 
which may then form complexes with up to three molecules of LF and/or EF (each bound LF/EF 
molecule “occupies” two neighboring PA subunits). The resulting complexes, which are known as 
lethal toxin (LeTx) and edema toxin (EdTx), respectively, are then internalized via clathrin-dependent 
receptor-mediated endocytosis  [446,447] and delivered to early endosomes where the complex is 
sorted to the vesicular regions and preferentially incorporated into intraluminal vesicles  [448]. 
Subsequently, the prepore undergoes an acidic pH-dependent conformational change to form a cation-
selective, ion-conducting channel  [449–451]. This channel/pore is thought to participate in the 
unfolding of LF and EF, and functions in their translocation into the lumen of the intraluminal vesicles 
or into the cytoplasm, probably with the aid of cytosolic components  [452–456]. Following 
transportation to late endosomes, back fusion of intraluminal vesicles with the limiting membrane 
delivers the toxic factors, which were “trapped” inside the vesicles lumen, to the cytoplasm [448]  
(for review about the cellular routing of the anthrax toxin, see [442,457]). Once in the cytoplasm, LF 
functions as a zinc metalloproteinase that specifically cleaves the N-termini of MKK/MEK proteins 
(kinases of mitogen-activated protein kinases), blocking their signaling activity [458–466]. EF is a 
Ca
2+/calmodulin activated adenylate cyclase (AC) that acts by elevating the intracellular level of cyclic 
AMP (cAMP), upsetting water homeostasis, destroying the delicate balance of intracellular signaling 
and impairing neutrophil functions [440,467– 472] (Figure 6).  Toxins 2010, 2  
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Figure 6. Cellular trafficking of anthrax toxin. 1. The toxins are secreted as 3 polypeptides: 
protective antigen (PA; 83 kDa), lethal factor (LF; 90 kDa) and edema factor (EF; 89 kDa) 
(see 3D structure (PDB Entry: PA- 1acc; LF-1j7n; EF- 1y0v). In the left panel, the colors 
of the different proteins correspond to those in the scheme; 2. PA binds to cellular receptor 
(ATR/TEM8; CMG2); 3. Cell-surface furin protease cleaves PA into an N terminal PA63 
(63 kDa) and C terminal PA20 (20 kDa) fragments; 4. Receptor bound PA63 self 
associates into a homoheptamer (“prepore”) that can bind up to 3 molecules of LF and/or 
EF; 5. The complex internalized via clathrin-dependent receptor mediated endocytosis;   
6. In the early endosomes (EE), the complex is sorted to the vesicular region and 
preferentially incorporated into intraluminal vesicles. The acidic environment of the 
endosome induces a conformational change in the prepore that turns into a channel/pore 
and functions in the translocation of LF and/or EF to the lumen of intraluminal vesicles or 
to the cytoplasm; 7. Following transportation to late endosome (LE), back fusion of 
intraluminal vesicles with the limiting membrane delivers the “trapped” toxic factors to the 
cytoplasm; 8. In the cytoplasm, LF functions as a zinc metalloproteinase that cleaves the N 
termini of MKK/MEK proteins, blocking their signaling activity. EF acts as a 
Ca
2+/calmodulin activated adenylate cyclase that dramatically elevates cytoplasmic cAMP 
level and consequently disrupts normal cellular activities. 
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Liu et al [421] were the first to introduce and apply a new concept in which replacing the natural 
furin cleavage site in anthrax PA protein (such cleavage must occur on the cell surface in order to 
achieve binding and internalization of a catalytic LF and EF) with a sequence recognized by a 
tumor-associated protease may confer the recombinant molecule with the ability of targeting the 
protease overexpressing cells. To this end, in two mutated PA proteins, PA-L1(named also PrAg-L1) 
and PA-L2, the natural furin recognition site was replaced by sequences susceptible to cleavage by 
MMP-2 (gelatinase A) and MMP-9 (gelatinase B) that are reported to be related to invasion and Toxins 2010, 2  
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metastasis in various human cancers [473–476]. The toxic catalytic polypeptide that has been used in 
this study was a fusion between the ADP-ribosylation domain of Pseudomonas exotoxin A and amino 
acids 1–254 of LF (LFN), which contains the PA binding domain that proved sufficient to achieve 
translocation of a fused “passenger” polypeptide to the cytosol of cells in a PA-dependent 
process [477–479]. By combining the re-engineered PA with the fusion toxic polypeptide (which was 
denoted FP59), the researchers have demonstrated selective killing of MMP-overexpressing human 
tumor cell lines while sparing nontumorigenic normal cells. Protection against challenge from 
PA-L1/L2 plus FP59 by MMP inhibitors further demonstrated that cell killing is highly dependent on 
the MMPs activity expressed by the tumor cells. Furthermore, specific eradication of MMP 
overexpressing tumor cells in a co-culture model indicated that PA activation occurred on the tumor 
cell surface and not in the culture supernatant. Activation of MMPs on the cell membrane by plasmin 
and/or membrane-anchored MMP, together with binding to cell surface receptors, were proposed as 
factors that may contribute to the retention of soluble active MMPs on the surface of tumor cells [421]. 
In contrast to the enzymatically active polypeptide of PE, DT and RIPs, which strongly inhibit 
protein synthesis causing the death of the intoxicated cell (see above), inactivation of mitogen-
activated protein kinase kinases by the action of anthrax lethal factor (LF) was found to selectively kill 
cells in which an activated MAPK pathway is required for their survival. This is similar to observed 
for cells bearing the V600E mutation in B-Raf, a serine/threonine kinase immediately upstream of 
MEK1/2 in the of the ERK MAPK cascade. The mutation, which was demonstrated mainly in 
melanoma but also in other human malignancies, “locks” the molecule in a constitutively active state, 
making the cell dependent on the constitutive activation of the ERK pathway for survival [480–483]. 
However, although specific toxicity toward B-Raf mutant melanoma cells has been observed both in 
vitro and in xenograft melanoma tumors in mice [481–484], development of LeTx variants with lower 
in vivo toxicity and high tumor specificity would be required for use in human cancer patients [485]. 
For the purpose of using LF as a targeted toxic polypeptide with superior specificity, a modified 
LeTx (PA-L1/LF) composed of LF and MMP activated PA protein was tested in mice xenograft 
models of human tumors. As expected, the PA-L1/LF showed lower toxicity to mice than wild-type 
toxin and has a potent anti-tumor activity. Surprisingly, anti-tumor activity was observed not only 
against human melanomas with B-Raf V600E mutation (due to direct toxicity against these cells), but 
also against other human tumor types including colon and lung carcinomas, and mouse tumors, 
regardless of their B-Raf status. Tumor histology and in vivo angiogenesis assays suggested that these 
effects can be attributed to indirect targeting of tumor vasculature and angiogenic processes 
(expression of MMPs has been shown to be upregulated in angiogenic lesions [486–489]), in which 
mitogen-activated protein kinase (MAPK) signaling pathways play a central role  [422,490]. Later 
in vitro studies on endothelial proliferation, invasion, and tube formation showed that activated LeTx 
acts by impairing microvascular endothelial cell invasion and migration in the absence of endothelial 
cell death [423]. Another intriguing observation was that the PA-L1/LF administration showed higher 
anti-tumor efficacy than does the wild-type toxin, probably because of greater bioavailability and 
longer half-life of PA-L1(relative to PA) in circulation [422].  
Treatment with PA-L1/LF also delayed tumor growth and improved long-term survival in mice 
with orthotopically implanted anaplastic thyroid carcinoma (ATC) xenografts. The antitumorogenic 
effect was comparable with that achieved by the multikinase inhibitor, sorafenib, which is currently Toxins 2010, 2  
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under evaluation for clinical use in patients with papillary thyroid carcinoma (PTC). As was already 
found in previous studies [422,423], the therapeutic effect of PA-L1/LF was mediated by the potent 
antiangiogenic activity of the drug, which did not cause any significant systemic toxicity [424]. 
4.1.2. Targeting Malignant Cells Overexpressing the Urokinase Plasminogen Activator System  
Plasminogen is an inactive precursor of plasmin, a serine protease present in plasma and 
extracellular fluid and is active in the process of fibrinolysis and degradation of extracellular matrix 
(ECM) components [491]. One of the naturally occurring plasminogen activators is the urokinase-type 
plasminogen activator (uPA), a serine protease secreted as an inactive pro-enzyme (pro-uPA) that 
efficiently converted by plasmin or kallikrein into uPA, which in turn cleaves plasminogen to generate 
the active plasmin in a positive feed-back mechanism. The catalytic efficiency of these reactions is 
further increased upon binding of pro-uPA/uPA and plasminogen/plasmin to membranal receptors, 
resulting in reciprocal zymogen activation on the cell surface. The initial proteolytic event leading to 
the initiation of plasmin generation on the cell surface is still under study [492–498]. While quite 
restricted in normal tissues, expression of pro-uPA and its receptor, uPAR, was found to be elevated in 
a significant number of solid tumors. Moreover, the presence of this proteolytic system which confers 
the tumor mass with the ability to degrade ECM proteins is associated with increased tumor tissue 
invasiveness and metastatic potential [499,500].  
To target tumor cells that overexpress the urokinase plasminogen activator system, the furin 
cleavage site in anthrax PA protein was replaced by sequences that are specifically cleaved by uPA. 
The modified PA was then combined with FP59, a fusion between the ADP-ribosylation domain of 
Pseudomonas exotoxin A and amino acids 1-254 of LF (see above). In the presence of pro-uPA and 
plasminogen, the recombinant complex (PrAg-U2  +  FP59) was demonstrated to be activated 
selectively on the surface of uPAR-expressing tumor cells from a broad range of human cancers of 
different origins, and ultimately resulted in specific tumor cell eradication [425,427]. Subsequent in 
vivo studies have demonstrated efficient suppression of different murine tumors growth and 
eradication of established tumors with limited toxicity to normal tissue upon local and systemic 
administration of the complex  [426,428]. 100% tumor regression and 30% complete histologic 
remission after systemic administration of tolerated doses of PrAg-U2+FP59 were documented in an in 
vivo athymic nude mouse model of human non–small cell lung cancer (NSCLC) [429].  
The requirement of two activating proteolytic events by two different tumor-associated proteases 
may confer the toxic agent with superior cell-type specificity and further attenuate its toxicity to 
normal tissues. In an elegant work performed by Liu et al [430], an intermolecular complementation 
approach was used for the targeting of tumor cells having both MMP and uPA activities which are 
overproduced by tumor tissues and are implicated in cancer cell growth and metastasis   
[435–439,499,500]. To this end, the authors exploited the findings that the anthrax LF binding site 
spans two adjacent monomers of cleaved PA in the oligomeric prepore. Each monomer contains three 
subsites which play a role in the binding of LF. However, the functional LF binding site is composed 
of a combination of subsites contributed by two adjacent subunits: subsite I and III form one monomer 
and subsite II from the neighboring subunit [501,502]. By mutating LF binding subsite III on an MMP 
activated PA (PrAg-L1) and subsite II on uPA activated PA (PrAg-U2), assembly of PA heptamer in Toxins 2010, 2  
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which every LF binding site contains the inactivating subsite III or subsite II mutation will occur 
following activating cleavage by either MMP or uPA, respectively. However, adding a mixture of 
these modified PA proteins to cells that have both MMP and uPA activities would generate two 
subunits that can randomly assemble into a heptamer in which up to three functional LF binding sites 
may be generated by intermolecular complementation between the two types of mutated subunits. In 
order to test the hypothesis that requirement of two tumor-associated activating proteolytic events may 
attenuate toxicity to normal tissues, an in vivo toxicity assay in mice was performed by intraperitoneal 
administration of a mixture containing subsite III mutated PrAg-L1 (PrAg-L1-I210A), subsite II 
mutated PrAg-U2 (PrAg-U2-R200A) and the toxic FP59 chimeric polypeptide. Indeed, results showed 
decreased toxicity in comparison to administration of a mixture of PrAg-L1, PrAg-U2 and   
FP59 (where either MMP or uPA proteolytic activity was sufficient to generate a functional LF 
binding prepore). 
When the combination of PrAg-U2-R200A and PrAg-L1-I210A (with FP59) was evaluated in 
treatment of three mouse tumor types (B16-BL6 melanoma, T241 fibrosarcoma, and LL3 Lewis lung 
carcinoma), a strong anti-tumor activity was observed. In contrast, the tumors showed little or no 
response to treatment with the individual proteins, demonstrating the necessity of intermolecular 
complementation between these engineered PA/PrAg proteins for the execution of a potent tumoricidal 
activity. In an anti-tumor efficacy comparing assay, the combination of PrAg-U2-R200A and 
PrAg-L1-I210A was at least as effective as an equivalent dose of PrAg-U2. However, given that the 
maximum tolerated dose of PrAg-U2-R200A/PrAg-L1-I210A is higher than that of PrAg-U2, the 
complementing mixture achieves higher tumor specificity [430]. 
4.2. Intracellular Protease Activated Toxins 
The life cycle of many viruses depends upon viral proteases for the cleavage of high molecular 
weight precursor viral proteins in order to yield functional products or by catalyzing the processing of 
the structural and non-structural proteins that are necessary for assembly and morphogenesis of viral 
particles. A partial list of human disease-associated viruses encoding protease(s) in their genomes 
include flaviviruses such as: hepatitis C virus (HCV), West Nile virus (WNV), dengue fever virus 
(DFV) and yellow fever virus (YFV); retroviruses such as HIV-1; picornaviruses such as 
coxsackievirus, poliovirus and hepatitis A virus; nidoviruses such as coronaviruses (CoV), including 
the severe acute respiratory syndrome (SARS) causative SARS-CoV; and herpesviruses such as 
varicella-zoster virus (VZV) and Epstein-Bar virus (EBV)  [503–505].  As expression of the viral 
protease distinguishes an infected cell from surrounding healthy tissue, limiting virus production and 
spread by a viral-protease activated toxin that specifically eradicates infected cells may comprise an 
attractive antiviral approach (Figure 1). Selected preclinical studies in the field are described in the 
following chapter. Information about the reviewed intracellular activated toxins is also summarized 
in Table 3. 
4.2.1. Targeting HIV Infected Cells 
The half-lives of proteins in a living cell range from a few seconds to many days. Features of 
proteins that confer metabolic instability are called degradation signals, or degrons. The N-end rule Toxins 2010, 2  
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degron (N-degron), which was the first to be discovered, relates the in vivo half-life of a protein to the 
identity of its amino-terminal residue. In eukaryotes, the N-degron comprises at least two determinants: 
a destabilizing N-terminal residue and internal lysine/s that function as acceptor site/s for the 
formation of a multi-ubiquitin chain that “marks” the ubiquitin-protein conjugates as a substrate for 
proteosomal degradation. Destabilizing residues in mammalian cells can be hierarchically divided into 
three classes: Primary (type 1 (Arg, Lys or His) or type 2 (Ile, Leu, Phe, Tyr or Trp)), secondary (Asp, 
Glu or oxidized Cys) and tertiary (Asn, Gln or Cys) (reviewed in [506–511]).  
In a comprehensive study by Falnes et al [512], the in vivo stability and cytotoxicity of diphtheria 
toxin-based polypeptides, artificially modified to initiate with short sequences derived from the FLAG 
peptide epitope differing only in their N-terminal amino acids, were assessed. According to their 
findings, when the first N terminal amino acid of the modified toxins were Phe, Tyr, Trp, Asp, Asn, 
Glu, Gln, Lys, Arg or His, the proteins were highly unstable, with half-lives in the range 0.2–1.6 hours, 
while the toxins initiated with either of the remaining amino acids were considerably more stable, with 
half-lives ranging from 3 to >12 hours. 
An in vitro study in reticulocyte lysates indicated that the ten N terminal amino acids that confer the 
toxin with short in vitro half life were also the most destabilizing ones in vivo. Moreover, cytotoxicity 
assays in Vero cells showed a clear correlation between the in vivo stability and the cytotoxicity of the 
proteins, although the difference in cytotoxicity between the wild-type DT-A fragment and the least 
stable mutant was only ~20-fold in compared to ~100-fold difference in intracellular half-life [512]. 
Alexander Varshavsky suggested previously the construction of a new kind of toxins where a signal 
that inactivates the toxin, e.g. a degradation signal, can be cleaved off by a viral protease, resulting in 
selective intoxication of virally infected cells. He denoted such toxins “sitoxins” (signal-regulated, 
cleavage mediated toxins)  [506]. For the construction of such viral-protease activated sitoxins, 
Falnes et al designed fusion proteins composed of a FLAG peptide containing an N-terminal 
phenylalanine (a destabilizing amino acid according to the N-end rule), followed by an HIV-1 protease 
(HIV-1 PR) cleavage sites that is positioned upstream to a chimeric sequence between DT-A and the 
first PA-binding 255 amino acids of the anthrax LF, the LFN fragment, which was also shown to be 
destabilized by the addition of a degradation signal for N-end-rule-mediated degradation [513]. The 
rationale behind this construct was that following anthrax PA-mediated translocation into the 
cytoplasm of uninfected cells, the modified toxin would be rapidly degraded by virtue of its 
destabilizing N-degron, resulting in attenuated cytotoxic activity against these uninfected cells. In 
contrast, cleavage of the construct by the HIV-1 protease whose activity has been documented in the 
cytosol of acutely infected cells [514–518] would result in the removal of the destabilizing N degron 
from the chimeric toxin, exposing a new N terminal amino acid. As HIV-PR cleavage in each of its 
two recognition sequences that were chosen (TATIM*MQRG or VSQNY*VIVQ) generates a 
stabilizing N terminal residue (methionine or valine, respectively) according to the N-end rule, a long-
life toxin with a potent cytotoxic activity is generated in HIV infected cells which leads to their 
destruction. Indeed, in vitro and in vivo simulating experiments showed that when the constructs were 
pre-digested with HIV-PR, both stability and cytotoxicity of the chimeric toxins was considerably 
augmented, proving that the concept of stabilizing a protein through specific proteolytic removal of a 
degradation signal works in practice. However, no selective eradication of HIV infected cells was Toxins 2010, 2  
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observed following treatment with non pre-treated constructs, probably because of low cytosolic HIV-1 
PR activity (no proteolytic processing of the constructs were detected in HIV-infected cells) [433].  
In another study, which was performed by Law et al [434], HIV protease-activated toxins were 
designed on the basis of the type III maize ribosome-inactivating protein, which in its native form is 
synthesized as inactive precursor (pro-RIP) and is activated by proteolytic removal of a 25 amino-acid 
inhibitory internal peptide in-planta [218,219]. In this work, the first and the last 10 residues of the 
internal inactivation region were replaced with two HIV-PR recognition sequences, and an 11 
amino-acids transduction peptide derived from the HIV-1 Tat protein was fused to the N-termini of the 
modified RIPs for promoting cell entry  [519]. These modifications resulted in the generation of 
re-engineered pro-RIPs which underwent an efficient cleavage in vitro by recombinant HIV-PR or 
in vivo (in HIV infected cells) by the viral encoded protease. Upon treatment of infected cells, the 
N-glycosidase and anti-viral activities of the modified cleavable RIPs were found to be higher than 
those of an uncleavable-nonactivated pro-RIP and resembled those of an activated mutant in which the 
inhibitory region was genetically removed. The cytotoxic activity of the cleavable RIPs against 
infected cells was not reported, but cytotoxicity toward uninfected cells was found to be lower than 
that of the activated mutant. Thus, the fact that the cleavable toxins behave more like a constitutively 
active form toward infected cells and in a similar way to a non-activated form toward uninfected cells, 
may suggest that they are specifically activated by the HIV protease and demonstrates the possibility 
of using this cleavable internal inactivation region as a switch to activate the toxin inside infected 
cells [434]. 
5. Concluding Remarks 
Treating cancer and chronic viral infections are among the most challenging goals in modern 
medicine. The recent integration of modified plant and bacterial toxins based therapies (and 
particularly immunotoxins with anti-tumor activity) into clinical research and application adds new 
weapons to the arsenal against these refractory diseases. Cumulative knowledge about toxins’ structure 
and mechanism of action, as well as recent progress and breakthroughs in the fields of cell biology, 
immunology, virology, molecular biology and nanotechnology, enabled the development of different 
targeting strategies that are crucial for converting a lethal toxin into a therapeutic agent (see Figure 1). 
However, clinical application of engineered toxins still faces many challenges. Two major problems 
associated with systemic administration of immunotoxins are: 1. lack of specificity resulting from the 
presence of the target antigen/receptor also being present on healthy tissue (“target dependent 
toxicity”); 2. Undesired intoxication of healthy tissue due to the immunotoxin binding to cell surface 
components rather than specifically to its target antigen/receptor (“target independent toxicity”). 
Whereas the first problem directly relates to the target and its expression/body-distribution profile; the 
second relates to the nature of the therapeutic agent itself.  
The most common toxicities in patients treated with immunotoxins are vascular leak syndrome 
(VLS) and hepatotoxicity, caused by non-specific binding of the toxic or the targeting moiety of the 
immunotoxin to endothelial and hepatic cells, respectively (for review, see [11,520,521]). Regarding 
this issue, Baluna et al have found that sequences of three amino acids in ricin toxin (and in other 
proteins associated with vascular leak syndrome) might cause endothelial damage by a mechanism Toxins 2010, 2  
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involving disruption of integrins, independently of the “classical” cell killing mediated by the toxin’s 
enzymatic activity [522]. By screening a panel of recombinant ricin A chains with mutations in this 
sequence or in amino acids flanking it in the three-dimensional structure, a mutant form of RTA 
showing diminished VLS in mice was isolated [523,524]. 
While pharmacokinetics issues and non-specific toxicity are common problems associated with the 
development of many drugs and particularly with the development of chemotherapeutic agents; 
immunogenicity is a major challenge distinguishing immunotoxins from small molecule-based 
therapy. Immunotoxins generally contain at least one non-human component which might be the 
bacterial/plant derived toxic moiety and/or an antibody from animal origin. Consequently, anti-drug 
antibody formation may be induced in immune-competent patients, resulting in a compromised 
treatment efficiency caused by the decrease in the level of circulating functional agent. The issue of 
human-anti mouse antibody (HAMA) formation against immunotoxins, in which the targeting moiety 
is a monoclonal antibody produced by hybridoma cells, has been overcome to a great extent by the 
development of chimeric, humanized and fully human antibodies using recombinant DNA technology 
(reviewed by  [525,526]). Attempts to use polyethylene glycol (“PEGylation”)  [527–529] and 
immunosuppressive agents  [105,107,530–532] have led to different success rates in reducing the 
immunogenic response against non-human components of immunotoxins. Deletion of B-cell and 
T-cell epitopes located on the surface of the toxic moieties is another option for reducing their 
immunogenicity. Recent studies conducted by Onda et al revealed seven major conformational B-cell 
epitopes on the PE38 molecule [533]. By mutation of specific large hydrophilic amino acids on the 
surface of the PE38 component in the immunotoxin BL22 (see above), most of the B cell epitopes 
were eliminated and a new fully functional immunotoxin which is significantly less immunogenic to 
mice was created  [534]. Taking advantage of this knowledge, Oh et al have created a bispecific 
cytotoxic polypeptide in which human epidermal growth factor (EGF) and interleukin-4 (IL-4) are 
linked to the B-cell epitopes-deleted PE38. When administrated to a mouse model of metastatic breast 
carcinoma, immunogenicity was reduced by about 90% (in comparison to the non-mutated construct) 
with no apparent loss of anti-tumor activity [535]. 
Concerning protease activated toxins and toxin based suicide gene therapy, clinical data is scarce as 
most developments in this field have not been evaluated clinically. However, it is conceivable that the 
specificity issues will remain relevant also for these agents as the transcription or proteolytic activity 
that execute their toxicity are rarely associated exclusively with a diseased cell, but rather, as was 
previously mentioned, have also a physiological role in healthy tissue. As in the case of immunotoxins, 
immunogenicity may also be a problem that must be overcome when treating immuno-competent 
patients with protease activated toxins or toxin based suicide gene therapy, either because of the 
immunogenicity of the cleavable toxin or the immunogenicity of the viral vecto.  
In conclusion, toxin-based therapy is a versatile and dynamic research area with a great application 
potential, as demonstrated in this review. However, further research is required in order to improve the 
efficiency and safety of toxin-based agents. Investments in the development of delivery and targeting 
techniques are definitely required in order to achieve this goal, but nevertheless the basic research on 
the structure and mechanism of natural toxins should not be abandoned. The deeper our knowledge 
about this unique family of secreted polypeptides, the easier for us to harness their great potential for 
our own benefit. Toxins 2010, 2  
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